Roquefort Therapeutics PLC - London-based biotechnology company - Says Midkine in vitro experiments completed with company’s oligonucleotides reducing high MDK levels in cancer cells. ‘These positive results demonstrate the pre-clinical proof of principle in cancer for the antisense oligonucleotide drug development program and underpin the company’s ability to progress to in vivo studies and clinical trials in due course targeting MDK in cancer,’ it says. On patent portfolio, has filed patents in Australia and UK to protect the composition of truncated MDK, mRNAs and antisense oligonucleotides. Adds it is working on publishing a prospectus, completing the acquisition of Oncogeni Ltd and £1.0 million fundraise.

Current stock price: 8.5 pence

12-month change: up 26%

Copyright 2022 Alliance News Limited. All Rights Reserved.